<DOC>
	<DOC>NCT00307931</DOC>
	<brief_summary>An open-label multi-center single-cohort study to assess the safety and efficacy of certolizumab pegol for the treatment of signs and symptoms of active Crohn's disease in Greek patients who have previously responded to infliximab but who no longer have a sustained response or became intolerant to infliximab</brief_summary>
	<brief_title>Certolizumab Pegol for Treatment of Adult Greek Patients With Moderate to Severe Crohn's Disease Who Failed Infliximab</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>â€¢ Adult men and women with Crohn's disease previously responsive to infliximab who became nonresponsive or intolerant Symptomatic obstructive intestinal strictures Bowel resection within 4 weeks Current total parenteral nutrition Short bowel syndrome Concomitant disease or pathological condition that could interfere with Crohn's disease or to be harmful for the well being of the patient.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>Certolizumab pegol</keyword>
	<keyword>Cimzia</keyword>
	<keyword>Crohn's disease</keyword>
	<keyword>Greek patients</keyword>
</DOC>